Jasco, Roswell Park Cancer Institute ink cancer agent collaboration
BUFFALO, N.Y.—Roswell Park Cancer Institute (RPCI) and Jasco Pharmaceuticals LLC have announced they will collaborate to advance the development of an investigational pharmacological therapy with the potential to treat solid-tumor cancers and hematologic malignancies. The partners will jointly pursue further development of Jasco's lead agent, JP-11646, including pharmacokinetic/pharmacodynamic analysis to determine efficacy, toxicity and cell response. RPCI will provide preclinical research infrastructure and services to help accelerate development and move the agent to clinical trials.
"This collaboration brings Jasco's unique kinase inhibitor platform together with Roswell Park's comprehensive expertise in the development of novel therapies for oncology and the treatment of patients," said Jasco CEO Eugene Baldino. "It's a great fit, and one that I know will reduce the development timeline of this promising agent, making it available to patients sooner."